
The study identified the RNA-binding protein RBMS3 as a key regulator of sorafenib resistance in hepatocellular carcinoma (HCC). RBMS3 loss enhances angiogenesis and resistance by increasing ANGPT2 expression and secretion. Mechanistically, RBMS3 recruits TRIM21 to facilitate K48-linked ubiquitination and degradation of ANGPT2. RBMS3 deletion correlates with increased angiogenesis and sorafenib resistance in HCC tissues. Notably, targeting ANGPT2 restores sorafenib sensitivity in RBMS3-deficient cells, suggesting a potential therapeutic approach.
Like
Save
Share